IBE:BMEIberdrola SA Analysis
Data as of 2026-05-22 - not real-time
$32.05
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
IBEX Limited is trading well below its discounted cash‑flow derived fair value, offering a clear margin of upside. The stock sits just beneath a key resistance level while comfortably above its support zone, and the moving‑average hierarchy shows the short‑term average above the mid‑term average, hinting at a modest bullish bias. Technical momentum remains supportive with a positive MACD histogram and an RSI positioned in the upper half of its range, suggesting continued buying pressure but also caution against overextension. Fundamentally, the company delivers solid top‑line growth, strong return on equity and healthy cash generation, all at a price‑to‑earnings multiple dramatically lower than the industry average. The recent earnings call and press release underscore continued investment in AI‑enabled service platforms, which could further bolster revenue streams. While volatility is elevated and beta hovers around one, the combination of undervaluation, stable liquidity and a resilient business model supports a cautiously optimistic stance.
Investors should weigh the near‑term technical resilience against the broader market’s risk appetite, as the current “Extreme Greed” sentiment may amplify short‑term price swings. Over the medium to long horizon, the gap between market price and intrinsic value, together with consistent cash flow generation, makes a case for adding exposure, provided risk tolerance aligns with the sector’s inherent dynamism.
Investors should weigh the near‑term technical resilience against the broader market’s risk appetite, as the current “Extreme Greed” sentiment may amplify short‑term price swings. Over the medium to long horizon, the gap between market price and intrinsic value, together with consistent cash flow generation, makes a case for adding exposure, provided risk tolerance aligns with the sector’s inherent dynamism.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Positive MACD and SMA alignment indicating short‑term bullish bias
- Price near resistance with elevated volatility
- Undervaluation relative to DCF fair value
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Revenue growth outpacing industry peers
- Strong ROE and cash flow generation
- Significant upside potential to intrinsic value
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Sustained AI‑driven service expansion
- Robust free cash flow supporting future reinvestment
- Long‑term price gap to discounted cash‑flow estimate
Key Metrics & Analysis
Financial Health
Revenue Growth16.80%
Profit Margin7.52%
P/E Ratio10.0
ROE33.11%
ROA12.98%
Debt/Equity37.95
P/B Ratio2.7
Op. Cash Flow$62.1M
Free Cash Flow$31.6M
Industry P/E39.1
Technical Analysis
TrendNeutral
RSI63.7
Support$27.26
Resistance$33.58
MA 20$29.88
MA 50$28.79
MA 200$33.40
MACDBullish
VolumeStable
Fear & Greed Index91.5
Valuation
Fair Value$58.13
Target Price$37.50
Upside/Downside17.00%
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.01
Volatility53.59%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.